Fagron N.V.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARSUF research report →
Companywww.fagron.com
Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines.
- CEO
- Rafael Padilla
- IPO
- 2017
- Employees
- 3,828
- HQ
- Nazareth, BE
Price Chart
Valuation
- Market Cap
- $1.95B
- P/E
- 20.03
- P/S
- 1.92
- P/B
- 3.30
- EV/EBITDA
- 11.64
- Div Yield
- 1.12%
Profitability
- Gross Margin
- 51.47%
- Op Margin
- 15.50%
- Net Margin
- 9.56%
- ROE
- 17.29%
- ROIC
- 11.09%
Growth & Income
- Revenue
- $951.81M · 9.16%
- Net Income
- $90.99M · 12.95%
- EPS
- $1.24 · 12.73%
- Op Income
- $146.16M
- FCF YoY
- 63.52%
Performance & Tape
- 52W High
- $27.00
- 52W Low
- $20.03
- 50D MA
- $26.73
- 200D MA
- $25.15
- Beta
- 0.38
- Avg Volume
- 698
Get TickerSpark's AI analysis on ARSUF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ARSUF Coverage
We haven't published any research on ARSUF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARSUF Report →